$4m series A for gene testing co:
This article was originally published in Clinica
Gene Security Network (GSN), a Portola Valley, California company that is developing molecular diagnostic tests using data informatics, has closed a series A financing led by Claremont Creek Ventures. Other investors include Sequoia Capital; Huntington Reproductive Centre; and Marissa Mayer, Google's vice-president of search products and user experience. GSN will use the funds to commercialise its Parental Support technology, which the company claims can test for multiple genetic diseases from a single cell. The technology is designed for use in pre-implantation genetic diagnosis during in vitro fertilisation.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.